Image

Effect of Telitacicept on Transitional Regulatory B Cells in Patients With Systemic Lupus Erythematosus

Effect of Telitacicept on Transitional Regulatory B Cells in Patients With Systemic Lupus Erythematosus

Recruiting
18-70 years
All
Phase N/A

Powered by AI

Overview

The effect of Telitacicept treatment on the changes of transitional regulatory B lymphocyte T1, T2B cell subsets and plasma blasts and the expression levels of cytokines IL-10, IL-35, April and BAFF in SLE.

Eligibility

Inclusion Criteria:

  1. The diagnosis meets the 2019 EULAR/ACR classification criteria for SLE;
  2. Age 18-70 years old;
  3. To be on a stable SLE regimen, participants were required to receive standard treatment at least 1 month prior to treatment with a biologic (Telitacicept);
  4. Lupus activity Index score (SELENA-SLEDAI) ≥ 8 at screening;
  5. Positive anti-nuclear antibody or anti-DSDNA antibody;
  6. Combined antiphospholipid syndrome should meet the diagnostic criteria: that is, meet one clinical criterion and one laboratory criterion.

Exclusion Criteria:

  1. Active infections (such as shingles, HIV infection, active tuberculosis, etc.) during the screening period;
  2. Central nervous system disease (including epilepsy, psychosis, organic encephalopathy syndrome, cerebrovascular accident, encephalitis, central nervous system vasculitis) caused by SLE or not caused by SLE in the last 2 months;
  3. Have active hepatitis or a history of severe liver disease;
  4. Patients with immune deficiency, uncontrolled severe infection, and active or recurrent digestive ulcer;
  5. Pregnant women, breastfeeding women and men or women who have planned to have a baby in the last 12 months;
  6. Allergic reaction: history of allergic reaction to human biological products;
  7. Those who received live vaccine within the last month;
  8. Participants who have participated in any clinical trial within 28 days prior to initial screening/or 5 times the half-life of the study compound (taking an older time);
  9. B cell targeted therapy, such as rituximab or epazumab, within one year;
  10. Use tumor necrosis factor inhibitors and interleukin-receptor blockers within one year;
  11. Patients receiving intravenous gamma globulin (IVIG), prednisone ≥ 100 mg/d for more than 14 days within one month or undergoing plasmapheresis;
  12. Psychopaths with depression or suicidal thoughts.

Study details
    Telitacicept
    Systemic Lupus Erythematosus
    Therapy

NCT06137053

Yanfeng Hou

27 January 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.